Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Cell Therapy Products Equipment Supplied In Europe
11 equipment items found
by:TQ Therapeutics GmbH based inPlanegg, GERMANY
TQx is developing a modular target cell-specific modification platform including relevant technology components for the generation of gene modified cell therapy ...
Manufactured by:Bioquell PLC, an Ecolab Solution based inAndover, UNITED KINGDOM
The Bioquell Qube is a configurable isolator integrated with Bioquell’s Hydrogen Peroxide Vapor technology. From its unique design to rapid cycle times, the Bioquell Qube ensures your aseptic workspace needs are met for a safe and productive working ...
by:Treefrog Therapeutics based inPessac, FRANCE
$100,000 Funding: We fund your research over 2 years in the academic lab of your choice. You spend the money how you like on your project, so that you can give it your best shot. Just Science: Any PhD level scientist can apply anonymously by submitting a one-page research rationale and a graphical abstract. We select ideas, not resumes. No Hassle: The application process is fast. We don’t ...
Manufactured by:TC BioPharm based inHolytown, UNITED KINGDOM
TC BioPharm’s cell banks have been developed as a resource for clinical development of cost-effective, safe and efficacious therapeutic treatments and ultimately, the ability to treat more patients. These T cell banks provide TC BioPharm with core technology to develop a deep portfolio of next-generation CAR-T products directed against a ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK00X: Kiadis is evaluating preclinical programs with K-NK-cell therapies for the treatment of hematologic and solid ...
Manufactured by:Cytena based inFreiburg, GERMANY
Faster than Ever Before: By automating labor-intensive and time-consuming steps, the F.SIGHT 2.0 significantly streamlines Cell Line Development (CLD), Cell & Gene therapy, as well as Single-cell Omics workflows. The F.SIGHT 2.0 is the fastest single-cell dispenser that isolates both unlabeled and green fluorescent cells. With our patented, highly efficient and gentle single-cell technology, ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK003: A phase 1 study evaluating NK cells as a treatment for patients with relapse and refractory acute myeloid leukemia (AML). This study was designed based on promising clinical proof-of-concept data from two studies, one at MD Anderson Cancer Center and one at HCPA in ...
Manufactured by:Sartorius AG based inGoettingen, GERMANY
The Recombumin® product portfolio are the highest quality, animal and human origin-free recombinant human albumins commercially available. Our highly pure, safe and consistent albumins enable you to formulate with ...
by:Thermo Fisher Scientific, LIMS & Laboratory Software based inPhiladelphia, PENNSYLVANIA (USA)
Cell Therapy Systems—a proven choice for clinical cell therapy manufacturing. As you move from basic cell therapy research to the clinic, high-quality GMP-grade cell therapy ancillary materials and proper documentation are essential to getting it right the ...
Manufactured by:c-LEcta GmbH based inLeipzig, GERMANY
DENARASE is a recombinantly produced endonuclease from Serratia marcescens. It is applied for the degradation of undesired DNA and RNA during the manufacturing of biopharmaceutical products – namely viral ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK002: A phase 2 clinical study evaluating haplo-identical NK cells to prevent post-transplant relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This study was designed based on promising clinical proof-of-concept data from MD Anderson Cancer Center. The phase 2 trial for K-NK002 will be conducted in collaboration with the Bone Marrow Transplant Clinical ...